Mechanistic Insights Into Survodutide, a Dual Glucagon/GLP-1 Receptor Agonist, for Obesity Treatment
Time: 12:30 pm
day: Day One
Details:
- Exploring the potential of dual and triple receptor agonists targeting multiple pathways involved in energy regulation, such as GLP-1, GIP, and glucagon receptors, to achieve weight loss with improved tolerability profiles
- Evaluating their clinical and metabolic benefits, and their potential to address gastrointestinal side effects while maintaining potent weight loss efficacy
- Understanding receptor interactions and signalling pathways used by these multireceptor agonists to optimise their therapeutic potential and identify patient populations that may benefit from these innovative approaches
